By Wendy Diller
Bristol-Myers Squibb Co.'s acquisition of Medarex this summer did more than thrust the company deeply into the antibody world....
Bristol-Myers aims to become an oncology powerhouse in the next five years. Through M&A, alliances, and internal R&D, Bristol-Myers is building an armamentarium of oncology assets that allows it to take multiple "shots on goal." It is leveraging its past experiences in the field as it also adds new skill sets in biologics, market access, and biomarkers. But the market has become more competitive, as companies look to participate in one of the few growth areas of pharma. Bristol, like others, is carving out space in the Avastin-ineligible or -intolerant portion of the market, particularly in the gastrointestinal, colorectal, and head-and-neck cancer areas. Even if successful, current late-stage development projects aren't likely to contribute much to revenues before 2011-and oncology products have slow ramp-ups. With a patent cliff looming in 2012, the company needs new products now.
By Wendy Diller
Bristol-Myers Squibb Co.'s acquisition of Medarex this summer did more than thrust the company deeply into the antibody world....
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.